SARS-CoV-2及其优势变异株mRNA加强针对西班牙瓦伦西亚医护人员感染与住院预防效果的随时间变化研究
在西班牙瓦伦西亚社区医护人员中采用检测阴性病例对照设计,评估SARS-CoV-2 mRNA疫苗预防有症状感染和住院的效果。结果显示第二剂后12-120天对感染的保护效果在Delta和Omicron优势期均随时间下降,加强针可显著恢复疫苗效果,且对住院的预防效果在两剂后保持稳定。
要点
- 第二剂后12-120天对感染aVE在Delta期为64.8%(BNT162b2)和59.4%(mRNA-1273),Omicron期为61.1%和85.1%。
- 第二剂后超过120天对感染aVE下降,加强针后aVE为64.0%(BNT162b2受种者)和65.9%(初始mRNA-1273受种者)。
- 无论变异株,两剂后预防住院aVE为87.0%(BNT162b2)和89.0%(mRNA-1273)。
核心结论
- 在Omicron优势期,医护人员接种两剂Moderna-mRNA-1273在第二剂后120天内对预防感染和住院高度有效。
- 第二剂后120天疫苗效果下降可被加强针显著恢复,且辉瑞疫苗的恢复幅度更大。
- 两种mRNA疫苗在整个研究期间对COVID-19住院的预防效果保持稳定。
研究设计与样本
- 检测阴性病例对照设计,纳入2021年1月至2022年3月期间接受SARS-CoV-2 PCR或抗原检测的医护人员。
- 病例为诊断检测阳性者,对照为检测阴性者。
- 采用公式aVE = (1 - 比值比) × 100计算调整疫苗效果。
主要发现
- Delta优势期,第二剂后12-120天对感染aVE为64.8%(BNT162b2)和59.4%(mRNA-1273),超过120天后分别降至21.2%和42.2%。
- Omicron优势期,第二剂后12-120天对感染aVE为61.1%(BNT162b2)和85.1%(mRNA-1273),超过120天后分别降至36.7%和24.9%。
- 接种mRNA-1273加强针后,aVE为64.0%(BNT162b2受种者)和65.9%(初始mRNA-1273受种者)。
- 无论变异株,两剂后预防住院aVE为87.0%(BNT162b2)和89.0%(mRNA-1273)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to evaluate the effectiveness of SARS-CoV-2 mRNA vaccines in preventing infection and hospitalization among healthcare workers (HCWs) in the Valencian Community (Spain), considering vaccination timing, dose number, and predominant variant. METHODS: A test-negative case-control design estimated vaccine effectiveness against symptomatic disease and hospitalization due to SARS-CoV-2. HCWs who underwent PCR or antigen testing for SARS-CoV-2 from January 2021 to March 2022 were included. Cases had a positive diagnostic test, while controls had negative tests. Adjusted vaccine effectiveness (aVE) was calculated using the formula: aVE = (1 - Odds ratio) × 100. RESULTS: During the Delta variant's predominance, aVE against infection within 12-120 days post-second dose was 64.8 % (BNT162b2) and 59.4 % (mRNA-1273), declining to 21.2 % and 42.2 %, respectively, after 120 days. For the Omicron variant, aVE within 12-120 days post-second dose was 61.1 % (BNT162b2) and 85.1 % (mRNA-1273), decreasing to 36.7 % and 24.9 %, respectively, after 120 days. After a booster dose of mRNA-1273, aVE was 64.0 % (BNT162b2 recipients) and 65.9 % (initial mRNA-1273 recipients). Regardless of variant, aVE for hospitalization prevention after 2 doses was 87.0 % (BNT162b2) and 89.0 % (mRNA-1273). CONCLUSION: The administration of two doses of Moderna-mRNA-1273 against SARS-CoV-2 in HCWs proved to be highly effective in preventing infections and hospitalizations in the first 120 days after the second dose during the predominance of the Omicron variant. The decline in VE after 120 days since the administration of the second dose was significantly restored by the booster dose administration. This increase in VE was greater for the Pfizer vaccine. COVID-19 hospitalization prevention remained stable with both mRNA vaccines throughout the study period.
引用
- Jiménez-Sepúlveda N, Gras-Valentí P, Chico-Sánchez P, et al. Effectiveness of mRNA booster doses in preventing infections and hospitalizations due to SARS-CoV-2 and its dominant variant over time in Valencian healthcare workers, Spain. Vaccine. 2024. PMID: 38760269. doi:10.1016/j.vaccine.2024.05.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。